Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 10;15(4):567–574. doi: 10.1093/ecco-jcc/jjaa184

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 4. — Cumulative risk of clinical relapse in patients with ulcerative colitis [UC], treated to target of clinical remission, who achieve: [A] persistent symptomatic and endoscopic remission with either [green] concurrent histological remission on both endoscopic assessments [HR/HR] or [red] ongoing histological activity on either or both endoscopic assessments [HA/HR, HR/HA, or HA/HA]; [B] persistent symptomatic and endoscopic remission with either [green] concurrent histological remission on last endoscopic assessments [-/HR] or [red] ongoing histological activity on last endoscopic assessments [-/HA]; [C] persistent symptomatic and endoscopic remission with either [green] concurrent histological remission on both endoscopic assessments [HR/HR] or [red] ongoing histological activity on both endoscopic assessments [HA/HA]. HA, histologic activity; HR, histologic remission.